Brief: Argenx To Buy Forte Biosciences For $2.20 Bln
27/07/2026 06:07
BRIEF-Argenx To Buy Forte Biosciences For $2.20 Bln July 27 (Reuters) - argenx SE ARGX.BR:
TO ACQUIRE FORTE BIOSCIENCES, INC., ADDING FIRST-IN-CLASS ANTI-CD122 ANTIBODY, FB102, TO ITS IMMUNOLOGY PIPELINE
TO BUY FORTE BIOSCIENCES FOR $77 PER SHARE IN CASH, EQUITY VALUE $2.20 BILLION
ACQUISITION EXPECTED TO CLOSE IN Q3 2026
WILL BE FUNDED ENTIRELY FROM CASH ON HAND
POSITIVE FB102 PHASE 1B DATA IN CELIAC DISEASE WAS SHARED LAST YEAR, WITH PHASE 2 DATA EXPECTED IN SECOND HALF OF THIS YEAR
Source text: ID:nGNEQfrhD
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))